Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2024-04-23 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于2023年度计提资产减值准备及核销资产的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shanghai Medicilon Inc. regarding the company's 2023 asset impairment provisions and asset write-offs. It details the amounts of impairment losses and write-offs, references accounting standards, and includes opinions from the audit committee, board of directors, and supervisory board. The document is relatively short (1940 characters) and serves as a formal disclosure of specific financial adjustments rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a regulatory announcement about asset impairment and write-offs, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Audit Report or Earnings Release. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-04-23 Chinese
美迪西：公司章程（2024年4月修订）
Governance Information Classification · 100% confidence The document is titled "上海美迪西生物医药股份有限公司章程" which translates to "Articles of Association of Shanghai Medicilon Inc." It contains detailed company governance rules, including chapters on general provisions, business scope, shares, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution and audit, notices and announcements, mergers, amendments to the articles, and other provisions. The content is a comprehensive set of internal governance rules and company bylaws, not a financial report, earnings release, or announcement. It does not contain financial statements or audit reports but rather the company's internal rules and governance structure. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the articles, not a brief announcement or summary.
2024-04-23 Chinese
美迪西：关于使用自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding the use of idle funds for cash management. It details the amount, purpose, types of financial products, risk control measures, and the board's approval of the cash management plan. There are no financial statements or detailed financial results presented. The document is a formal disclosure about financing activities related to cash management, not a full financial report or earnings release. This fits the definition of a Capital/Financing Update (CAP) as it updates on the company's use of funds and investment decisions related to capital management.
2024-04-23 Chinese
美迪西：2023年度审计报告及财务报表
Regulatory Filings
2024-04-23 Chinese
美迪西：2023年年度报告
Annual Report Classification · 100% confidence The document is titled "2023 年年度报告" which translates to "2023 Annual Report". It is issued by Shanghai Medicilon Inc. and covers the fiscal year from January 1, 2023 to December 31, 2023. The content includes detailed financial data such as revenue, net profit, cash flow, and asset information, as well as management discussion and analysis, risk factors, corporate governance, and audit opinions. The document is lengthy (15,000 characters) and contains comprehensive financial statements and analysis, not just an announcement or summary. It also includes auditor's report with unqualified opinion and signatures from company officers, which is typical for an annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2024-04-23 Chinese
美迪西：2023年度独立董事述职报告（马大为）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Report for the year 2023" from Shanghai Medicilon Inc. It details the independent director's duties, attendance at board and shareholder meetings, communication with auditors, review of financial reports, oversight of related party transactions, and other governance activities during the year 2023. The content is a detailed narrative of the independent director's work and evaluation of company governance and financial reporting for the year. It is not a full annual report or audit report but a specific report by an independent director on their duties and observations for the year. This type of document fits best under Board/Management Information (MANG), as it relates to board member activities and governance oversight rather than financial results or audit opinions. The document length is 4482 characters, which is substantive and contains detailed information, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-23 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.